Allozyne was a clinical stage[clarification needed] biotechnology company headquartered in Seattle's biotech and high tech innovation corridor.[where?]

Allozyne was founded in 2005 by California Institute of Technology researchers, and was incubated[clarification needed] by Accelerator Corporation.

Their two platforms, Caesar and Vigenère, enable the creation of novel therapeutics that address unmet medical need associated with these diseases.

These biociphering platforms have opened the door to new protein therapeutic configurations including antibody-toxin, antibody-antibody, long acting as well as others.

[7] On July 15, 2010, Allozybe announced the signing of an exclusive license agreement with The Scripps Research Institute for Click chemistry.